The group of Dr. Meyer at the Institut für Medizinische Mikrobiologie, Immunologie und Hygiene at the Technische Universität München is dedicated to developing innovative treatment options to meet the increasing threat by antibiotic resistances. In particular gram-negative, carbapenem-resistant infections pose a massive clinical challenge as there are very few - if any - treatment options left. We have identified two innovative molecule classes, which open novel therapeutic prospects. Within a BMBF funded project, we aim to further develop both compound classes in collaboration with two Helm-holtz Institutes in Neuherberg (structure analysis) and Braunschweig (medicinal chemistry). The focus of this project is the pathogen-targeted optimization of the compounds with respect to pathogen species, expressed antibiotic resistances, and other resistance enhancing mechanisms.